Tag: immune thrombocytopenia (ITP)

April 14, 2022 Off

Sanofi Announces Positive Phase 1/2 Study Results of Rilzabrutinib in People with Immune Thrombocytopenia

By Author

Sanofi has announced the positive results from the Phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine.

March 31, 2017 Off

argenx kicks off phase II of immune thrombocytopenia treatment study

By Dino Mustafić

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has started dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP).